Effect of dexmedetomidine on lung protection during one-lung ventilation in patients with COPD

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064842

Enrollment

Unknown

Registered

2022-10-19

Start date

2022-10-17

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Experimental group:Dexmedetomidine

Control group:Normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. ASA I - III; 2. COPD GOLD I-II patients; 3. Elective thoracoscopic lobectomy.

Exclusion criteria

Exclusion criteria: 1. Spinal deformity; 2. Severe hepatic and renal insufficiency; 3. Patients with severe sinus bradycardia, atrioventricular conduction obstruction, arrhythmia, myocardial ischemia; 4. Patients with cognitive dysfunction or unable to participate in the evaluation of postoperative recovery quality and analgesia; 5. Hemoglobin less than 110g/L.

Design outcomes

Primary

Measure	Time frame
Oxygenation index;	—

Countries

China

Contacts

Public ContactRen Zhendong

Pengzhou People's Hospital

1009508505@qq.com+86 15828610112

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026